---
title: "Elutia Inc. (ELUT.US)"
type: "quote"
locale: "en"
url: "https://longbridge.com/en/quote/ELUT.US.md"
symbol: "ELUT.US"
name: "Elutia Inc."
industry: "生物技术"
---

# Elutia Inc. (ELUT.US)

| Item | Detail |
|------|--------|
| Industry | 生物技术 |
| Location | 美股市场 |
| Website | [elutia.com](https://elutia.com) |

## Company Profile

Elutia Inc.是一家商业阶段的公司，专注于开发和商业化用于神经刺激和乳房重建的药物洗脱生物制品，主要在美国运营。该公司分为三个业务部门：设备保护、女性健康和心血管。公司提供 EluPro，用于容纳心脏植入电子设备，如起搏器和内部除颤器；以及 CanGaroo，旨在减轻植入电子设备带来的并发症和合成外壳的不足。它还提供 ProxiCor 用于心脏组织修复和心包闭合；Tyke，一种用于新生儿和婴儿患者心脏结构修复的细胞外材料；以及 VasCure，一种用于修复或重建外周血管的补丁材料

## Financial Score

> *Longbridge Financial Score™ — Proprietary multi-factor rating model by [Longbridge](https://longbridge.com). This score is independently calculated by Longbridge and is not affiliated with any third-party rating agency.*
> Updated: 2026-02-23T04:30:15.000Z

**Overall: C (0.48)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 146 / 403 |
| Industry Median | D |
| Industry Average | C |

- **Style**: Blend - Stocks in which the company has both growth and mature businesses.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

### Score Analysis

**Style Score**: 

#### Growth Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 24.08% |  |
| Net Profit YoY | 51.16% |  |

#### Value Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| P/B Ratio | -1.05 |  |
| Dividend Ratio | 0.00% |  |


**Size Score**: 

#### Market Cap Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 46.22M |  |

#### Revenue Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue | 21.75M |  |


**Multi Score**: C

#### Profit Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 60.13% | A |
| Profit Margin | -121.73% | E |
| Gross Margin | 55.76% | B |

#### Growth Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 24.08% | A |
| Net Profit YoY | 51.16% | B |
| Total Assets YoY | -39.25% | E |
| Net Assets YoY | -9.15% | D |

#### Cash Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| Cash Flow Margin | -82.15% | D |
| OCF YoY | 24.08% | A |

#### Operating Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| Turnover | 0.56 | B |

#### Debt Score: E

| Indicator | Value | Rating |
|-----------|-------|--------|
| Gearing Ratio | 249.35% | E |


```chart-data:radar
{
  "title": "Longbridge Financial Score - Elutia Inc.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Profit",
      "grade": "B",
      "indicators": [
        {
          "name": "ROE",
          "value": "60.13%",
          "rating": "A"
        },
        {
          "name": "Profit Margin",
          "value": "-121.73%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "55.76%",
          "rating": "B"
        }
      ]
    },
    {
      "name": "Growth",
      "grade": "B",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "24.08%",
          "rating": "A"
        },
        {
          "name": "Net Profit YoY",
          "value": "51.16%",
          "rating": "B"
        },
        {
          "name": "Total Assets YoY",
          "value": "-39.25%",
          "rating": "E"
        },
        {
          "name": "Net Assets YoY",
          "value": "-9.15%",
          "rating": "D"
        }
      ]
    },
    {
      "name": "Cash",
      "grade": "C",
      "indicators": [
        {
          "name": "Cash Flow Margin",
          "value": "-82.15%",
          "rating": "D"
        },
        {
          "name": "OCF YoY",
          "value": "24.08%",
          "rating": "A"
        }
      ]
    },
    {
      "name": "Operating",
      "grade": "B",
      "indicators": [
        {
          "name": "Turnover",
          "value": "0.56",
          "rating": "B"
        }
      ]
    },
    {
      "name": "Security",
      "grade": "E",
      "indicators": [
        {
          "name": "Gearing Ratio",
          "value": "249.35%",
          "rating": "E"
        }
      ]
    }
  ]
}
```

### Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
|------|------|--------|--------|-----------|----------|------|--------|
| 01 | ADMA生物制药 (US.ADMA) | A | A | A | B | B | A |
| 02 | Kiniksa Pharmaceuticals (US.KNSA) | B | A | A | B | A | A |
| 03 | Stoke Therapeutics (US.STOK) | A | A | B | A | B | A |
| 04 | Rigel制药 (US.RIGL) | A | A | A | C | B | A |
| 05 | OpGen (US.OPGN) | B | A | A | A | B | A |

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -1.75 | 244/604 | - | - | - |
| PB | -1.05 | 489/604 | - | - | - |
| PS (TTM) | 2.13 | 55/604 | 3.79 | 3.02 | 1.59 |
| Dividend Yield | 0.00% | - | - | - | - |

## Institutional View

### Analyst Rating Distribution

> As of 2026-01-16T05:00:00.000Z

Total Analysts: **2**

| Rating | Count | Percentage |
|--------|-------|-----------|
| Buy | 2 | 100% |
| Overweight | 0 | 0% |
| Hold | 0 | 0% |
| Underweight | 0 | 0% |
| Sell | 0 | 0% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 1.08 |
| Highest Target | 5.00 |
| Lowest Target | 2.00 |

## References

- [Company Overview](https://longbridge.com/en/quote/ELUT.US/overview.md) - Shareholders, executives, business segments
- [Financials](https://longbridge.com/en/quote/ELUT.US/norm.md) - Income statement, balance sheet, cash flow, distribution plan
- [Topics & Discussions](https://longbridge.com/en/quote/ELUT.US/topics.md) - Community topics and discussions

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.